Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M109,267Revenue $M42,750Net Margin (%)17.6Z-Score2.1
Enterprise Value $M134,179EPS $3.6Operating Margin %22.5F-Score6
P/E(ttm))16.3Cash Flow Per Share $0Pre-tax Margin (%)21.0Higher ROA y-yY
Price/Book13.310-y EBITDA Growth Rate %3.2Quick Ratio0.7Cash flow > EarningsY
Price/Sales2.95-y EBITDA Growth Rate %2.6Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-27.4ROA % (ttm)10.4Higher Current Ratio y-yN
Dividend Yield %5.9Insider Buy (3m)0ROE % (ttm)68.0Less Shares Outstanding y-yY
Payout Ratio %93.0Shares Outstanding M2,402ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKHOTCHKIS & WILEY 2014-06-30 Add0.93%$51.55 - $56.39
($54.16)
$ 45.14-17%Add 13358.6%4,949,118
GSKJohn Rogers 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 45.14-17%Add 49.33%988,772
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 45.14-17%Add 15.52%2,500,048
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 45.14-17%New holding, 270900 sh.270,900
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 45.14-17%Reduce -43.82%5,156,449
GSKJohn Rogers 2014-03-31 Add0.16%$50.9 - $56.66
($54.07)
$ 45.14-16%Add 57.21%662,150
GSKHOTCHKIS & WILEY 2014-03-31 Buy 0.01%$50.9 - $56.66
($54.07)
$ 45.14-16%New holding, 36773 sh.36,773
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 45.14-16%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 45.14-16%Sold Out0
GSKNWQ Managers 2014-03-31 Reduce-0.03%$50.9 - $56.66
($54.07)
$ 45.14-16%Reduce -28.91%148,800
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 45.14-13%Add 1702.13%423,500
GSKJohn Rogers 2013-12-31 Add0.19%$49.31 - $53.68
($51.87)
$ 45.14-13%Add 208.93%421,201
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 45.14-13%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 45.14-13%New holding, 83452 sh.83,452
GSKVanguard Health Care Fund 2013-12-31 Reduce-0.14%$49.31 - $53.68
($51.87)
$ 45.14-13%Reduce -55.18%644,881
GSKWarren Buffett 2013-12-31 Sold Out -0.02%$49.31 - $53.68
($51.87)
$ 45.14-13%Sold Out0
GSKJohn Rogers 2013-09-30 Add0.07%$50.27 - $52.96
($51.54)
$ 45.14-12%Add 246.35%136,344
GSKWarren Buffett 2013-09-30 Reduce-0.06%$50.27 - $52.96
($51.54)
$ 45.14-12%Reduce -76.57%345,819
GSKJohn Rogers 2013-06-30 Add0.03%$46.79 - $53.59
($50.77)
$ 45.14-11%Add 460.45%39,366
GSKJoel Greenblatt 2013-06-30 Sold Out -0.16%$46.79 - $53.59
($50.77)
$ 45.14-11%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK HOTCHKIS & WILEY 2014-06-304,949,1180.210.94+13358.6%
GSK James Barrow 2014-06-30270,9000.010.02New Buy
GSK John Rogers 2014-06-30988,7720.040.65+49.33%
GSK Charles Brandes 2014-06-302,500,0480.11.6+15.52%
GSK Ken Fisher 2014-06-3011,365,9030.471.3+1.35%
GSK Joel Greenblatt 2014-06-3083,52800.06+0.09%
GSK NWQ Managers 2014-06-30148,8500.010.08+0.03%
GSK John Hussman 2014-06-30323,5000.011.3
GSK Jean-Marie Eveillard 2014-06-30100
GSK Dodge & Cox 2014-06-3060,226,0502.513.1-0.27%
GSK Tweedy Browne 2014-06-30142,1180.010.16-0.34%
GSK PRIMECAP Management 2014-06-305,156,4490.210.3-43.82%
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29752.17view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12275.67view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14222view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12275.67view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      Tweedy Browne Global Value Fund's Top Picks for Q3 Oct 21 2014 
      Diamond Hill Capital Comments on GlaxoSmithKline PLC Oct 17 2014 
      Dodge & Cox’ Stock Fund Third Quarter 2014 Commentary Oct 16 2014 
      Ebola: Is The Cure Out There? Oct 14 2014 
      Guru Stocks at 52-Week Lows: GE, BHP, TOT, BP, GSK Oct 12 2014 
      Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF Sep 30 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Guru Stocks at 52-Week Lows: BHP, GSK, EC, VALE, ABB Sep 21 2014 
      Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF Sep 16 2014 


      More From Other Websites
      Director/PDMR Shareholding Oct 29 2014
      Dear Sanofi: Firing CEO Chris Viehbacher Is A Huge Mistake Oct 29 2014
      Should I Invest In GlaxoSmithKline Plc Now? Oct 29 2014
      After merger, where's Walgreen Boots Alliance headed? Oct 28 2014
      In Ebola Crisis, New Vaccine Candidates Show Uncertain Promise Oct 28 2014
      Ebola: The making of a $1 billion drug Oct 28 2014
      Novartis' precision M&A plan: CEO Oct 28 2014
      Recovering GlaxoSmithKline plc Won’t Be Cheap For Much Longer Oct 28 2014
      The Ebola Crisis In 3 Charts And 3 Articles Oct 27 2014
      Publication of Supplementary Prospectus Oct 27 2014
      Director/PDMR Shareholding Oct 27 2014
      Are GlaxoSmithKline plc’s Dividends Set To Disappoint? Oct 27 2014
      Drugmakers bet on Ebola vaccines, treatments Oct 26 2014
      Director/PDMR Shareholding Oct 24 2014
      J&J and Glaxo Ready to Collaborate for Ebola Vaccine Work Oct 24 2014
      Glaxo Gains on Q3 Earnings Beat and Restructuring Plans Oct 24 2014
      Head of GSK Ebola Vaccine Research: "Can We Even Consider Doing A Trial?" Oct 23 2014
      Drugmakers want indemnity Oct 23 2014
      Director/PDMR Shareholding Oct 23 2014
      [$$] GlaxoSmithKline Unveils Cost-Saving Plan, Considers IPO of HIV Business Oct 22 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK